Apoptose
Les inhibiteurs de l'apoptose sont des composés qui empêchent ou retardent le processus de mort cellulaire programmée, connu sous le nom d'apoptose. Ces inhibiteurs sont essentiels pour étudier les mécanismes de survie cellulaire et sont utilisés pour enquêter sur les maladies où l'apoptose est dysrégulée, telles que le cancer, les troubles neurodégénératifs et les maladies auto-immunes. En modulant l'apoptose, ces inhibiteurs peuvent aider au développement de thérapies visant à contrôler la mort cellulaire. Chez CymitQuimica, nous offrons une sélection complète d'inhibiteurs de l'apoptose de haute qualité pour soutenir vos recherches en biologie cellulaire, oncologie et domaines connexes.
Sous-catégories appartenant à la catégorie "Apoptose"
- ASK(9 produits)
- BCL(11 produits)
- Caspase(143 produits)
- FOXO1(3 produits)
- IAP(67 produits)
- Mdm2(12 produits)
- PD-1/PD-L1(139 produits)
- PDK(9 produits)
- PERK(25 produits)
- Sérine/thréonine kinase(19 produits)
- Survivant(14 produits)
- TNF(92 produits)
- c-RET(59 produits)
- p53(63 produits)
Affichez 6 plus de sous-catégories
6010 produits trouvés pour "Apoptose"
Trier par
Degré de pureté (%)
0
100
|
0
|
50
|
90
|
95
|
100
Pim-1 kinase inhibitor 10
CAS :<p>Pim-1 Kinase Inhibitor 10 (compound 13a) acts as both a competitive and non-competitive inhibitor of PIM-1/2 kinase, promoting cell apoptosis and displaying anticancer properties. Additionally, this compound triggers the activation of caspase 3/7 [1].</p>Formule :C21H13N3O3Couleur et forme :SolidMasse moléculaire :355.35CAR-2
CAS :<p>CAR-2 is a BODIPY-based photosensitizer that induces ferroptosis in photodynamic therapy (PDT) by targeting the endoplasmic reticulum (ER) and lipid droplets (LD). It exhibits phototoxicity against breast cancer cells with an IC50 of 0.01-0.02 μM and demonstrates antitumor efficacy in a 4T1 xenograft mouse model.</p>Formule :C27H23BF2I2N4O2Couleur et forme :SolidMasse moléculaire :738.114Tubulin polymerization-IN-6
Compound 5f, a potent tubulin polymerization inhibitor (IC50 = 1.09 μM), blocks cell migration, tube formation, and has anti-angiogenic effects.Formule :C19H21NO7Couleur et forme :SolidMasse moléculaire :375.37GRP78-IN-1
GRP78-IN-1 binds to GRP78 protein, inhibits cell growth, and triggers apoptosis in breast cancer; has -8.07 kcal/mol binding energy.Formule :C21H23FO3Couleur et forme :SolidMasse moléculaire :342.4Z-VAD
CAS :<p>Z-VAD is an irreversible pan-caspase inhibitor, suppressing multiple caspases including caspase-3, -6, -7, -8, and -9. Z-VAD induces autophagy in tumour cells.</p>Formule :C20H27N3O8Degré de pureté :98.961%Couleur et forme :SolidMasse moléculaire :437.44TNF-α-IN-14
CAS :TNF-α-IN-14, a potent TNFα inhibitor, exhibits a selective inhibition profile with an IC50 of 1.1 µM and demonstrates antiinflammatory properties (WO2001072735A2; compound 12) [1].Formule :C22H26O6Couleur et forme :SolidMasse moléculaire :386.44WYJ-2
CAS :<p>WYJ-2, a selective agonist for toll-like receptor 2/1 (TLR2/1), demonstrates an EC50 of 18.57 nM in HEK 293T cells transiently co-transfected with human TLR2 and TLR1. It induces pyroptosis and has shown anticancer activity against non-small cell lung cancer (NSCLC) [1].</p>Formule :C17H9F2N3O4Couleur et forme :SolidMasse moléculaire :357.27Anticancer agent 45
Anticancer agent 46, potent and selective, induces apoptosis, is cytotoxic to cancer cells, with low toxicity to human lymphocytes.Formule :C22H14ClN3O6S2Couleur et forme :SolidMasse moléculaire :515.95BNN27
CAS :BNN27 is an agonist of the TrkA receptor (TrkAreceptor) and the p75NTR receptor (p75NTR receptor), exhibiting neurotrophic and anti-apoptotic properties. It enhances levels of glutamate, GABA, and glutamine in the hippocampus and prefrontal cortex of rats, improving glutamate turnover. In a mouse model of amyotrophic lateral sclerosis (ALS), BNN27 demonstrates neuroprotective effects, shows anti-inflammatory properties in an experimental autoimmune encephalomyelitis (EAE) model, and exhibits retinal protection in a rat diabetes model. BNN27 also possesses blood-brain barrier permeability.Formule :C21H32O3Couleur et forme :SolidMasse moléculaire :332.477ASP9831
CAS :<p>ASP9831 is an orally active PDE4 inhibitor. It suppresses LPS-induced TNF-α production and exhibits anti-inflammatory properties. ASP9831 is useful in the study of steatohepatitis.</p>Formule :C20H23N3O3Couleur et forme :SolidMasse moléculaire :353.42EGFR-IN-47
EGFR-IN-47: strong oral EGFRL858R/T790M/C797S blocker, induces cell death; promising for NSCLC research. IC50: 0.01 μM.Formule :C29H35N7Couleur et forme :SolidMasse moléculaire :481.64Z-VA-DL-D-FMK
CAS :Z-VA-DL-D-FMK (Z-VA-DL-D(OH)-FMK) acts as an inhibitor of caspases. It irreversibly binds to caspases, enhancing the sensitivity to TNF-α and stimulating HIV replication in infected T cells ACH-2.Formule :C21H28FN3O7Couleur et forme :SolidMasse moléculaire :453.46NLRP3-IN-28
CAS :NLRP3-IN-28 (compound N77) serves as a potent inhibitor of NLRP3, effectively blocking Nigericin-induced pyroptosis with an EC50 of 0.07μM. Additionally, it mitigates inflammatory reactions in vivo [1].Formule :C12H9F3N2O3SCouleur et forme :SolidMasse moléculaire :318.27NLRP3-IN-26
CAS :<p>NLRP3-IN-26 (compound 15Z), with an IC50 of 0.13 μM, functions as an inhibitor of NLRP3. It is applicable in studies involving the DSS-induced colitis model [1].</p>Formule :C31H33ClN2O6SCouleur et forme :SolidMasse moléculaire :597.12TNF-α-IN-12
CAS :<p>TNF-α-IN-12, a TNF-α inhibitor with an IC50 of 0.1 μM, can reduce TNF-α blood levels [1].</p>Formule :C21H22O6Couleur et forme :SolidMasse moléculaire :370.4Tubulin/NRP1-IN-1
CAS :Tubulin/NRP1-IN-1 (compound TN-2) serves as a dual inhibitor targeting both Tubulin and NRP1, exhibiting IC50 values of 0.71 μM and 0.85 μM, respectively. This compound notably reduces the viability of prostate tumor cell lines and triggers apoptosis [1].Formule :C28H37N5O8Couleur et forme :SolidMasse moléculaire :571.62TOPOI/PARP-1-IN-1
CAS :Compound B6, also known as TOPOI/PARP-1-IN-1, is a dual inhibitor targeting TOPOI and PARP, exhibiting low cytotoxicity and oral activity with a PARP1 IC 50 of 0.09 μM. This compound effectively inhibits cancer cell proliferation and migration, induces cell cycle arrest at the G0/G1 phase, and triggers apoptosis. In murine models, TOPOI/PARP-1-IN-1 demonstrated a tumor growth inhibition rate (TGI) of 75.4% [1].Formule :C36H38Br2N4O2Couleur et forme :SolidMasse moléculaire :718.52PIM1-IN-3
PIM1-IN-3 (HL8) selectively blocks PIM1, induces Colo320 cell apoptosis, and may be researched for cancer.Formule :C27H25BrN6OCouleur et forme :SolidMasse moléculaire :529.43MJC13
CAS :<p>MJC13 is an FKBP52-targeting agent with antitumor activity, suitable for prostate cancer research.</p>Formule :C13H15Cl2NOCouleur et forme :SolidMasse moléculaire :272.17GLS1 Inhibitor-6
GLS1 Inhibitor-6: IC50=68nM, 220x more selective for GLS2, has anti-tumor and pro-apoptosis effects.Formule :C37H52N6O3SCouleur et forme :SolidMasse moléculaire :660.91
